PULSE the living trend engine
▲ Peaking Business

Teva autoimmune antibody notches ph. 2 win in celiac disease

5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

5sources
5articles
3velocity
+0%since first seen
1h agofirst detected

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

The brief

"Teva autoimmune antibody notches ph. 2 win in celiac disease" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.

Outlets currently covering the story include tradingview.com, Yahoo Finance, Investing.com India and WKZO. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.

This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.

Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 1h ago.

Quick answers

Why is "Teva autoimmune antibody notches ph. 2 win in celiac disease" trending?

Because 5 independent news sources published 5 articles about it in a short window — a coverage burst PULSE classifies as a trend.

How does PULSE measure this trend?

PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.

Is this trend still active?

The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.

Coverage (5)

Topics

Teva

Related trends